INSERM U590, Laboratoire de Cytologie Analytique, Faculte de Medecine Rockefeller, Universite Claude Bernard Lyon I, 69008 Lyon, France.
Lancet Oncol. 2011 Jul;12(7):693-702. doi: 10.1016/S1470-2045(10)70244-8. Epub 2010 Dec 14.
The large subunit of human ribonucleotide reductase, RRM1, is involved in the regulation of cell proliferation, cell migration, tumour and metastasis development, and the synthesis of deoxyribonucleotides for DNA synthesis. It is also a cellular target for the chemotherapeutic agent, gemcitabine. RRM1 has been studied in a large number of patients with different types of cancer, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, and biliary tract cancer, to establish its prognostic or predictive value when patients were treated with gemcitabine, and mRNA expression and genetic variants as determined by genotyping have in some cases been associated with clinical outcome of patients with cancer. Here, we review preclinical and clinical studies of RRM1 assessment and discuss the further steps in the development of this clinically pertinent biomarker.
人核糖核苷酸还原酶大亚基 RRM1 参与细胞增殖、细胞迁移、肿瘤和转移发展以及脱氧核苷酸的合成，用于 DNA 合成。它也是化学治疗药物吉西他滨的细胞靶标。RRM1 在大量不同类型的癌症患者中进行了研究，例如非小细胞肺癌、胰腺癌、乳腺癌和胆管癌，以确定患者接受吉西他滨治疗时的预后或预测价值，并且基因分型确定的 mRNA 表达和遗传变异在某些情况下与癌症患者的临床结果相关。在这里，我们回顾了 RRM1 评估的临床前和临床研究，并讨论了这一具有临床相关性生物标志物的进一步发展步骤。
